Примери за използване на Gmts на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
The SPRs and GMTs are displayed in Table 13.
The clinical relevance of the lower GMCs and GMTs is currently unknown.
In addition, OPA GMTs were in same ranges for both groups.
In Protocol 007 peak anti-HPV 6, 11, 16, 18 GMTs were observed at Month 7.
The GMTs levels depend on age and dengue serostatus at baseline.
Furthermore, in this study statistically significantly greater OPA GMTs were demonstrated for 10 of the 12 serotypes in common.
Afterwards, the GMTs declined through Month 24- 48 and then generally stabilized.
Table 7 compares the 1 month Postdose 3 anti-HPV 6, 11, 16, and 18 GMTs in 9- to 15-year-old boys with those in 16- to 26-year-old men.
In addition, OPA GMTs between subjects receiving Prevenar 13 with or without 2-PE were compared.
For the cross-reactive serotype 19A, the results did not suggest any differences in ELISA antibody GMCs and OPA GMTs between groups.
The antibody GMCs and OPA GMTs were lower after 2-dose for most vaccine serotypes.
GMTs were higher in girls and boys than in women aged 16 to 26 years, and higher in boys than in girls and women.
Rates of subjects with PRNT50≥1:10 and GMTs at Months 2, 6, 12, 24 and 36 are summarized in Table 3 for the ITT population.
At 1 year post vaccination,Menveo continued to be statistically higher than ACWY-PS for serogroups A, W-135 and Y, as measured by percentage of subjects with hSBA≥1:8 and GMTs.
Then, GMTs stabilize over the next 2 to 4 years and remain superior to pre-vaccination GMTs.
Immunogenicity was evaluated by comparing geometric mean titres(GMTs) of strain-specific serum haemagglutination inhibition(HAI) antibodies post dosing.
Table 5: GMTs and seroconversion rates in adult and paediatric subjects vaccinated with TIVc(V58P12 and V58P13).
The sequential administration of combined dTpa-IPV followed by Cervarix one month later tended to elicit lower anti-HPV-16 and anti-HPV-18 GMTs as compared to Cervarix alone.
Similar antibody GMCs and OPA GMTs were observed for all infants except a lower OPA GMT for serotype 5 in very preterm infants.
For most vaccine serotypes and serotype 19A,group comparisons did not suggest any differences post-booster dose in ELISA antibody GMCs and OPA GMTs between the HIV+/+ and HIV-/- groups, or the HIV+/- and HIV-/- groups.
The seroresponse rates and hSBA GMTs were high after the two-dose schedule in children against each of the vaccine antigens(Table 5).
A statistical analysis of non-inferiority was performed at Month 7 comparing cLIA anti-HPV 6, anti-HPV 11, anti-HPV 16, andanti-HPV 18 GMTs between individuals administered Gardasil 9 and individuals administered Gardasil.
In adults aged 50-59 years, OPA GMTs to all 13 serotypes in Prevenar 13 were non-inferior to the Prevenar 13 responses in adults aged 60-64 years.
One month after co-administration with a 10-valent pneumococcal conjugate vaccine, lower Geometric Mean antibody Concentrations(GMCs) and opsonophagocytic assay(OPA) antibody GMTs were observed for one pneumococcal serotype(18C conjugated to tetanus toxoid carrier protein).
The differences between hSBA GMTs in the 2-dose and the single dose groups at 1 year after vaccination were lower than those seen at 1 month post-vaccination.
After the first dose, Prevenar 13 elicited antibody levels,measured by both IgG GMCs and OPA GMTs that were statistically significantly higher when compared to levels prior to vaccination.
Table 4: GMTs and seroconversion rates(with 95% CI) in subjects 9 to< 18 years of age, 3 weeks after vaccination with Flucelvax Tetra or TIV1c/TIV2c- Per Protocol Set(V130_03).
One month after the booster dose increases of ELISA antibody GMCs and OPA GMTs were seen for each vaccine serotype and the cross-reactive serotype 19A, indicative of immunological memory.
GMTs were higher in girls and boys who received 2 doses of Gardasil 9(at either 0, 6 months or 0, 12 months) than in girls and women 16 to 26 years of age who received 3 doses of Gardasil 9(at 0, 2, 6 months) for each of the 9 vaccine HPV types.
Non-inferiority was established for all 4 influenza strains included in the Flucelvax Tetra,as assessed by ratios of GMTs and the differences in the percentages of subjects achieving seroconversion at 3 weeks following vaccination.